Rapid, Safe and Effective Vaccines for Global Health

There are significant obstacles facing vaccines in that they: Are slow to develop and manufacture; Often have sub-optimal levels, broadness and duration of protection; Use archaic growth systems and/or potentially toxic chemicals; Rely on exotic and unproven methods; Have limited flexibility/coverage; Require challenging storage conditions and distribution channels; Face skepticism in general population.

The SolaVAX™ method employs the use of a photochemical (riboflavin/vitamin B2) in combination with UV light in the UVA and UVB wavelength regions to carry out specific nucleic acid alterations in pathogens, rendering them non-infective while maintaining authentic antigen presentation. 

Potential attributes of SolaVAX™ vaccines include:

More complete antigen presentation (whole virus) to address emergent variants

Already contains multiple virus strains/multiple antigen variants = multivalent

Rapid manufacturing pivot to address emergent strains; not strain- or virus-dependent

Feasibility of low cost, geographically distributed, local manufacturing to address global needs

Does not rely on toxic inactivating chemicals that potentially compromise antigen conformation and add to manufacturing complexity

COVID-19

In preliminary experiments, SolaVAX™-CoV-2 vaccine-treated animals demonstrated:

Dramatically decreased viral load

Reduced lymphocytic infiltration and neutrophil accumulation

Increased alveolar air space

The SolaVAX™-CoV-2 investigational vaccine is estimated to be 2k to 20k times more effective on a weight/weight basis of dose compared to other inactivation methods.

References

A Whole Virion Vaccine for COVID-19 Produced via a Novel Inactivation Method and Preliminary Demonstration of Efficacy in an Animal Challenge Model (https://www.mdpi.com/2076-393X/9/4/340)

Apparatus used to produce photo-inactivated vaccine candidates